Danicopan Disease Interactions

Initiation of therapy with danicopan is contraindicated in patients with unresolved serious infection caused by encapsulated bacteria, including Neisseria meningitidis, Streptococcus pneumoniae, or Haemophilus influenzae type B. Complete or update vaccination against encapsulated bacteria at least 2 weeks prior to administration of the first dose of this drug; follow clinical vaccination guidelines for patients on complement inhibitors. Antibacterial drug prophylaxis is recommended in patients who require urgent therapy and who are not up to date on vaccinations.

Avoid use of danicopan in patients with severe liver dysfunction (Child-Pugh C); studies have not been conducted in this population. No dose adjustment of danicopan is required in patients with mild to moderate liver dysfunction (Child-Pugh A or B).